.com is pleased to announce a new with , CEO of Soligenix, Inc. (:)


 

Soligenix - SNGX

Soligenix, Inc. is a late stage company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2015 10-Q
CIK 0000812796
Fiscal Year End 12/31
Marketplace OTCQB
Profile Data
SIC – Industry Classification 2834 – Pharmaceutical preparations
Business Status Development Stage Company a/o Jun 10, 2013
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Christopher J. Schaber President, CEO
Richard Straube Senior VP, Chief Med. Officer
Oreola Donini Senior VP, Chief Scientific Officer
Joseph M. Warusz Vice President, Acting CFO, Principal Acct. Officer
Company Directors
Christopher J. Schaber Chairman
Keith Brownlie
Marco Brughera
Gregg Lapointe
Robert Rubin
Jerry Zeldis
Company Notes
  • Formerly=DOR BioPharma, Inc. until 9-2009
  • Formerly=Endorex Corp. until 12-01
  • Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers

Accounting/Auditing Firm

EisnerAmper LLP
101 West Avenue
P.O. Box 458
Jenkintown, PA, 19046
United States

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE